Showing results (1-10 of 1,159) with videos related to

Sort By:
Pageof 116
Herpes : the Journal of the IHMF|February 28, 2002
Recent developments in herpesvirus therapyL Naesens, E De Clercq
Clinical Chemistry|April 1, 1992
Acyclic adenine nucleoside phosphonates in plasma determined by high-performance liquid chromatography with fluorescence detectionL Naesens, J Balzarini, E De Clercq
International Journal of Cancer|August 15, 1990
Anti-retrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in vivo increases when it is less frequently administeredJ Balzarini, L Naesens, E De Clercq
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 1, 1992
Pharmacokinetics in mice of the anti-retrovirus agent 9-(2-phosphonylmethoxyethyl)adenineL Naesens, J Balzarini, E De Clercq
Current Opinion in Microbiology|March 6, 1999
New antivirals - mechanism of action and resistance developmentJ Balzarini, L Naesens, E De Clercq
Antiviral Research|July 1, 1991
Single-dose administration of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the prophylaxis of retrovirus infection in vivoL Naesens, J Balzarini, E De Clercq
Biochemical Pharmacology|July 28, 1999
N6-cyclopropyl-PMEDAP: a novel derivative of 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) with distinct metabolic, antiproliferative, and differentiation-inducing propertiesS Hatse, L Naesens, E De Clercq, et al.
Antimicrobial Agents and Chemotherapy|October 28, 2005
Mouse adenovirus type 1 infection in SCID mice: an experimental model for antiviral therapy of systemic adenovirus infectionsL Lenaerts, E Verbeken, E De Clercq, et al.
Biochimica Et Biophysica Acta|April 29, 1998
Selection and characterisation of murine leukaemia L1210 cells with high-level resistance to the cytostatic activity of the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl) adenine (PMEA)J Balzarini, S Hatse, L Naesens, et al.
Journal of Medical Virology|May 1, 1992
Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency miceJ Neyts, J Balzarini, L Naesens, et al.
Pageof 116